Zydus to Pay Astellas $120M to Resolve Patent Dispute

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Zydus to Pay Astellas $120 Million to Settle Patent Dispute Over Bladder Drug

Representational image (Image: News18)

N

News18•12-02-2026, 11:45

Zydus to Pay Astellas $120 Million to Settle Patent Dispute Over Bladder Drug

•Zydus Lifesciences will pay Astellas Pharma USD 120 million to resolve a patent litigation.
•The dispute concerned Myrbetriq, a medication for active bladder treatment.
•Zydus Pharmaceuticals USA, Inc., a subsidiary, entered the settlement agreement.
•Zydus will also pay a prepaid per unit licensing fee on generic Mirabegron sold in the US until September 2027.
•The agreement concludes all litigations between the companies, allowing Zydus to continue marketing its generic Mirabegron.

Read Full Article on News18 in English

✦

More like this

✦

More like this

The announcement comes days after local peer Lupin decided to settle its dispute with Astellas over the same drug for $90 million. Reuters

Zydus Life Settles Astellas Bladder Drug Patent Dispute for $120 Million

The BMC plans to start 25 more Aapla Dawakhana and three physiotherapy centres in the next financial year.

Zydus Lifesciences settles Mirabegron patent dispute with Astellas for $120 mn

Lupin Settles Mirabegron Patent Dispute with Astellas for $90 Million

Lupin Settles Mirabegron Patent Dispute with Astellas for $90 Million

Zydus Lifesciences

Zydus Lifesciences Shares Surge on USFDA Approval for Ammonium Lactate Cream

Glenmark Pharma US Arm to Launch Sodium Phosphate Injection, Distribution Begins April

Glenmark Pharma US Arm to Launch Sodium Phosphate Injection, Distribution Begins April

Representational image (Image: News18)

Alembic Pharma gets USFDA nod for generic anti-fungal solution